Federal Register Notice: FDA is making available a draft guidance for industry entitled Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. Its purpose is to assist sponsors in all phases of development of antiretroviral drugs for the treatment of HIV. It revises the guidance entitled Antiretroviral Drugs Using Plasma HIV RNA Measurements — Clinical Considerations for Accelerated and Traditional Approval issued in 10/2002. To download this guidance, click here. To view this notice, click here.